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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the comparative effects of different antibiotics in the treatment of adults and children with non-cystic fibrosis bronchiectasis.
B A C K G R O U N D
Description of the condition
Bronchiectasis is characterised by abnormal dilation of the airways
that is associated with a pathological mechanism of progressive
airway destruction, due to the ’vicious cycle’ of recurrent bacterial
infection, inflammatory mediator release, airway damage and sub-
sequent further infection (Cole 1986). The airways show chronic
inflammation with various features, including loss of ciliated ep-
ithelium and mucous gland hypertrophy. Bacterial colonisation
is facilitated by this loss of an integral epithelial structure (host
defence) which, in turn, triggers further immune responses and a
continuation of the inflammatory process. An understanding of
this cycle is central to the management of bronchiectasis as strate-
gies to arrest both inflammatory and bacterial components are re-
quired to limit the progression of lung injury. Typically microbi-
ology for bronchiectasis patients includesHaemophilus influenzae,
Streptococcus pneumoniae, Moraxella catarrhalis and, importantly,
Pseudomonas aeruginosa, though the microbiological profile differs
between adults and children with Pseudomonas more common in
adults and prevalent in only 0% to 6% of children. Pseudomonas
colonisation often occurs later in the natural progression of the
condition and may infer a worse prognosis in terms of symptoms,
exacerbations and loss of lung function (Evans 1996). In severe
cases, the cycle of lung infection may lead to repeated hospitalisa-
tion, chronic respiratory failure and death.
Most adult cases of bronchiectasis are either idiopathic or due to a
previous severe lung infection. However, treatable causes, such as
immune-deficiency, allergic bronchopulmonary aspergillosis, my-
cobacterial infection and recurrent aspiration may be identified in
aminority of cases (Pasteur 2010;Goeminne 2012;Wilson 2013).
One study found aproportionof caseswere associatedwith chronic
obstructive pulmonary disease (COPD) and connective tissue dis-
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eases (Loni 2015). Underlying causes can be determined in up to
70% of paediatric cases (Eastham 2004; Twiss 2005). Diagnosis
is based on a combination of clinical symptoms and high-resolu-
tion computerised tomography (HRCT) that show one or more
abnormally dilated bronchi (Chang 2010; Pasteur 2010). Symp-
toms may include chronic productive cough, wheeze and breath-
lessness, together with recurrent lower respiratory tract infections.
Colonisation with P. aeruginosa and frequent exacerbations are as-
sociated with accelerated decline in lung function (Evans 1996;
Martínez García 2007), and, along with impaired exercise capacity
and respiratory symptoms, reduced quality of life and hospitalisa-
tions (Wilson 1997; Finch 2015).
Management of bronchiectasis requires careful attention to spu-
tum clearance, bronchodilator therapy, and the prescription of an-
tibiotics (Welsh 2015). In the short term, the main aim is to re-
duce microbial load in order to reduce the severity and frequency
of exacerbations, thereby ameliorating symptoms and improving
quality of life (Pasteur 2010), with the longer-term aim of break-
ing the infection cycle, slowing the decline in lung function and
reducing mortality rates. Antibiotics have traditionally been re-
served for the treatment of acute infection/exacerbation although
there is possibly a role for prophylactic strategies in some cases.
Latterly the use of macrolides has attracted further interest and
trials have explored their prescription in bronchiectasis patients
(Wu 2014).
Global prevalence estimates are unclear because of variable diag-
nostic strategies (Weycker 2005), and higher prevalence rates in
low and middle income countries (Habesoglu 2011). Mortality
rates in England and Wales rose by 3% per year between 2001 to
2007 (Roberts 2010), and hospitalisations also increased by 3%
per year over a nine-year period in the USA (Seitz 2010). Higher
prevalence rates were associated with people over 60 years of age
and women, and varied by ethnicity (Chang 2003; Seitz 2012).
Recent data from a UK study suggests that incidence and preva-
lencemay be higher than previously estimated (Quint 2016).Over
a nine-year period to 2013, point prevalence rates per 100,000 rose
from 350.5 to 566.1 in women and from 301.2 to 485.5 in men.
This reflects an increase of more than 60% with almost 263,000
adults living with bronchiectasis in 2013. Similarly, the incidence
rates per 100,000 person-years rose from 21.2 to 35.2 in women
and from 18.2 to 26.9 in men. Representing an approximate in-
crease in new cases of 63% to over 15,000 in 2013. Bronchiec-
tasis is also associated with higher age-adjusted mortality rates,
with estimates 2.26 times higher in women and 2.14 times higher
in men compared to the general population (Quint 2016). The
disease has a significant impact on paediatric populations where
quality of life is worse for younger children and those with a more
frequent annual exacerbation rate (Kapur 2012). Global preva-
lence estimates are variable, ranging from conservative estimates
of 17.2 in the North-East of England (Eastham 2004), to 33.5 in
New Zealand (Twiss 2005), per 100,000 children under 15 years.
Rates may be higher in children from indigenous populations,
with estimates of 1 per 625 (160 per 100,000) in children from
the pacific islands (Twiss 2005), 15 per 1000 (1500 per 100,000)
in native central Australian Aborginal children, and 16 per 1000
(1600 per 100,000) in native Alaksan children (Singleton 2000;
Chang 2002).
The economic burden of bronchiectasis may be considerable but
little data is available. Data collected in 2001 in the USA re-
ported an additional 2.0 days in hospital, 6.1 more outpatient en-
counters and 27.2 more days of antibiotic therapy associated with
bronchiectasis (Weycker 2005). Estimates of the overall additional
annual costs of bronchiectasis range from USD 5681 to USD
7827, based on data collected between 2001 and 2009 (Weycker
2005; Seitz 2010; Joish 2013).
Description of the intervention
Bronchiectasis is characterised by daily coughing, sputum expec-
toration and recurrent respiratory infection. Serial infections often
culminate in bacterial colonisation with dilatation and inflamma-
tion of the airways. Whilst abnormalities may be pan-lobar (i.e.
throughout both lungs), infection may be limited to a single lung
lobe or manifest in a patchy distribution. Antibiotics are used to
reduce bacterial burden, to tackle the cycle of infection and tissue
damage (Cole 1984; Pasteur 2010). They may be administered
short-term (less than four weeks) to treat acute exacerbations or
for longer (≥ 4 weeks). Longer durations of antibiotics are used
for pathogen eradication, suppression of bacterial load or for anti-
inflammatory properties (e.g. macrolides). Several routes of ad-
ministration are available including: oral, inhaled and parenteral
routes, with analysis of sputum bacteriology informing the spe-
cific choice of antibiotic. Prescribing is also informed by clinical
context as well as bacteriology and sputum purulence is consid-
ered a reliable indicator of the need for treatment (Hill 1988). An-
tibiotics may therefore be prescribed before the results of sputum
bacteriology are obtained. Antibiotics are a frontline therapy for
the management of bacterial load in bronchiectasis but their use
is tempered with the need for considered use in the face of adverse
effects and increasing concerns over antibiotic resistance (Pasteur
2010).
How the intervention might work
A range of antibiotic strategies have been used to reduce bac-
terial load and re-infection rates in people with bronchiectasis,
including short-term prescriptions for acute exacerbations and
longer-term prophylactic use in patients with frequent exacerba-
tionswhere chronic sputumpurulence is a common feature (Evans
2003; Chalmers 2012). Longer-term use of antibiotics is not cur-
rently recommended as part of routine treatment (Valery 2012;
Wu 2014), but may be considered for patients with frequent ex-
acerbations (three or more per year requiring antibiotic therapy)
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(Pasteur 2010). Antibiotic choice is usually guided by sputum mi-
crobiology and patterns of local antibiotic resistance but treatment
is often started empirically with a broad spectrum oral or intra-
venous antibiotic until the specific pathogen has been isolated. If
there is more than one positive culture an antibiotic is selected
to cover both. However, dual therapy is likely where monother-
apy will not suffice, such as with Pseudomonas spp, a common
pathogen in bronchiectasis. Macrolide antibiotics may addition-
ally be prescribed for their potential anti-inflammatory properties
as well as antibacterial effects.
Why it is important to do this review
Evidence for the effectiveness of a range of treatment strategies
in bronchiectasis is limited by the number and quality of clinical
trials, including those on antibiotics, and the need for evidence on
head-to-head comparisons of antibiotics have been highlighted as
a key priority (Welsh 2015). The comparative cost-effectiveness
of within-class antibiotics, e.g. from different manufacturers, is
unclear but this type of evidence could be used to inform choice
of antibiotic, particularly in developing countries where use of
cheaper antibiotics may be more prevalent compared to developed
countries.
Therefore this Cochrane Review will include studies that directly
compare the effectiveness of two ormore antibiotics, as well as con-
sider issues relating to duration of treatment and mode of delivery.
We will endeavour to draw together existing evidence comparing
their effectiveness for non-cystic fibrosis bronchiectasis against key
outcomes identified by Welsh 2015. We are conducting this as a
Cochrane Review employing established methodology in accor-
dance with the recent evaluation of these standards versus alterna-
tive approaches (Page 2016). This Cochrane Review is being con-
ducted alongside four other closely-related reviews: Macrolide an-
tibiotics for non-cystic fibrosis bronchiectasis (Kelly 2016) ;Dual an-
tibiotics for non-cystic fibrosis bronchiectasis (Felix 2017a); Oral ver-
sus inhaled antibiotics for non-cystic fibrosis bronchiectasis (Spencer
2017); and Continuous versus intermittent antibiotics for non-
cystic bronchiectasis (Felix 2017b). .
O B J E C T I V E S
To evaluate the comparative effects of different antibiotics in
the treatment of adults and children with non-cystic fibrosis
bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs). We will in-
clude studies reported as full-text articles, those published as ab-
stracts only and unpublished data.
Types of participants
We will include adults and children (less than 18 years of age) di-
agnosed with bronchiectasis by bronchography or high-resolution
computed tomography who report daily signs/symptoms, such as
cough, sputum production, haemoptysis or those with recurrent
episodes of chest infections. We will exclude studies if patients
have been receiving continuous or high-dose antibiotics in the
four weeks before the start of the study, if they have a diagnosis of
traction bronchiectasis due to pulmonary fibrosis or if they have
received a diagnosis of cystic fibrosis.
Types of interventions
We will include studies that compare one antibiotic with another
where they are administered by the same deliverymethod, e.g. neb-
ulised vs nebulised, in order to isolate the effect of the antibiotic
rather than the delivery device. We will consider short-term use
(less than four weeks) for treating acute exacerbations and longer-
term use as a prophylactic (≥ four weeks) separately. Also we will
analyse generational comparisons (e.g. 3rd vs 4th generation flu-
oroquinolones) separately from between-class comparisons (e.g.
penicillin vs fluoroquinolones).
Types of outcome measures
Primary outcomes
We will include the following primary outcomes.
1. Exacerbation, e.g. frequency during follow-up or time to
first exacerbation.
2. Serious adverse events, defined according to Hansen 2015.
Secondary outcomes
We will include the following secondary outcomes for both short-
and long-term therapy.
1. Frequency of hospitalisations due to exacerbations of
bronchiectasis.
2. Response rates as defined by study authors (e.g. diary cards
of physician global assessment).
3. Sputum volume and purulence.
4. Measures of lung function (e.g. forced expiratory volume in
one second (FEV1)).
5. Systemic markers of infection (e.g. leucocyte count, C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR)).
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6. Adverse events (e.g. cardiac arrhythmias, gastrointestinal
symptoms, hearing impairment).
7. Deaths, all-cause and respiratory, which we will analyse and
report separately.
8. Emergence of resistance to antibiotics.
9. Exercise capacity (e.g. Six-Minute Walk Distance
(6MWD)).
10. Quality of life (e.g. St George Respiratory Questionnaire
(SGRQ) or QoL-B).
Reporting one or more of the outcomes listed here in the study is
not an inclusion criterion for the Cochrane Review.
Search methods for identification of studies
Electronic searches
We will identify studies from the Cochrane Airways Group’s Spe-
cialised Register (CAGR), which is maintained by the Informa-
tion Specialist for the Cochrane Airways Group. The CAGR con-
tains trial reports identified through systematic searches of bibli-
ographic databases, including the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL,
AMED and PsycINFO, and handsearching of respiratory journals
and meeting abstracts (please see Appendix 1 for further details).
We will search all records in the CAGR using the search strategy
in Appendix 2.
We will also conduct a search of ClinicalTrials.gov (
www.ClinicalTrials.gov) and the World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP)
portal (www.who.int/ictrp/en/). We will search all databases from
their inception to the present, and we will impose no restriction
on language of publication.
Searching other resources
We will check reference lists of all primary studies and review ar-
ticles for additional references. We will search relevant manufac-
turers’ websites for trial information.
We will search for errata or retractions from included studies pub-
lished in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and report the date that we perform this.
Data collection and analysis
Selection of studies
Two review authors, ES and LF, will independently screen all titles
and abstracts of all studieswe identify from the literature search and
will code them as either ’retrieve’ (eligible or potentially eligible/
unclear studies) or ’do not retrieve’. We will retrieve the full-text
study reports/publications of all articles in the ’retrieve’ category.
Two review authors, ES and LF, will independently screen the full-
text articles and identify studies for inclusion, and identify and
record reasons for exclusionof the ineligible studies.Wewill resolve
any disagreement through discussionor, if required,wewill consult
a third review author (SS or SJM). We will identify and exclude
duplicates and will collate multiple reports of the same study so
that each study rather than each report is the unit of interest in the
review. We will record the selection process in sufficient detail to
complete a PRISMAflowdiagram and ’Characteristics of excluded
studies’ table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data which we will pilot on at least one study that we
include in the review. One review author, LF, will extract study
characteristics from included studies. We will extract the following
study characteristics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors, AK and LF, will independently extract out-
come data from the included studies. We will note in the ’Charac-
teristics of included studies’ table if an included trial did not report
outcome data in a usable way. We will resolve any disagreements
by consensus or by consulting a third review author (SS or SJM).
One review author, LF, will transfer data into Review Manager 5
(RevMan 5) (Review Manager 2014). We will double-check that
LF has entered data correctly by comparing the data presented
in the systematic review with the study reports. A second review
author, AK, will spot-check the study characteristics for accuracy
against the trial report.
Assessment of risk of bias in included studies
Two review authors (AK and LF) will independently assess the
risk of bias for each included study using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We will resolve any disagreements by discussion
or by involving another review author (SS and SJM).Wewill assess
the risk of bias according to the following domains.
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1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as either high, low or
unclear and will provide a quote from the study report together
with a justification for our judgment in the ’Risk of bias’ table.
We will summarise the ’Risk of bias’ judgements across different
studies for each of the domains listed. We will consider blind-
ing separately for different key outcomes where necessary (e.g. for
unblinded outcome assessment, risk of bias for all-cause mortal-
ity may be very different than for a patient-reported pain scale).
Where information on risk of bias relates to unpublished data or
correspondence with a trial author, we will note this in the ’Risk
of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios and continuous
data as either mean difference or standardised mean difference
values. We will enter data presented as a scale with a consistent
direction of effect.
We will undertake meta-analyses only where this is meaningful i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense.
We will narratively describe skewed data reported as medians and
interquartile ranges.
Where a single trial hasmultiple trial arms, wewill include only the
relevant trial arms. If two comparisons (e.g. drug A versus drug B
and drugC versus drugB) are combined in the samemeta-analysis,
we will halve the comparison group to avoid double-counting.
Unit of analysis issues
In all included studies the unit of analysis will be the participant.
We will analyse exacerbation rates as rate ratios if the data are
available.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as abstract
only). Where this is not possible and we believe that the missing
data may have introduced serious bias, we will explore the impact
of including such studies in the overall assessment of results by a
sensitivity analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity, i.e.
when I² is greater than 50% (Deeks 2011)„ we will report it and
explore possible cause by prespecified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small study and publi-
cation biases.
Data synthesis
Wewill use a fixed-effectmodel for meta-analysis and will perform
a sensitivity analysis with a random-effects model.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
primary and secondary outcomes; exacerbations serious adverse
events, response rates, deaths and quality of life. We will use the
five GRADE considerations (study limitations, consistency of ef-
fect, imprecision, indirectness and publication bias) to assess the
quality of a body of evidence as it relates to the studies which con-
tribute data to the meta-analyses for the prespecified outcomes.
We will use methods and recommendations described in Section
8.5 (Higgins 2011) and Chapter 12 (Schünemann 2011)of the
Cochrane Handbook for Systematic Reviews of Interventions using
GRADEpro software (GRADEpro GDT 2016). We will justify
all decisions to downgrade or upgrade the quality of studies using
footnotes and we will make comments to aid the reader’s under-
standing of the Cochrane Review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Adults vs children.
2. Dose or schedule, or both.
3. Duration (prophylactic antibiotics).
4. Type of antibiotic.
We will use the following outcomes in subgroup analyses.
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1. Exacerbation duration (short-term therapy).
2. Exacerbation frequency (long-term therapy).
3. Hospitalisation.
4. Adverse events.
We will use the formal test for subgroup interactions in RevMan
5 (Review Manager 2014).
Sensitivity analysis
We plan to evaluate the impact of methodological study quality
by removing studies at high or unclear risk of bias according to the
following risk of bias domains: random sequence generation and
allocation concealment. We will use a fixed-effect model as well as
a random-effects model as part of our sensitivity analysis.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
Database Search frequency
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
8Head-to-head trials of antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Bronchiectasis search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
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8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Anti-Bacterial Agents Explode 1
#6 antibiotic* or anti-biotic*
#7 anti-bacteri* or antibacteri*
#8 *cillin
#9 *mycin or micin*
#10 *oxacin
#11 *tetracycline
#12 macrolide*
#13 quinolone*
#14 trimethoprim
#15 ceph*
#16 sulpha*
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #4 and #17
[In search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, bronchiectasis]
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